Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy

Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy

Abstract Background Blocking of the Tumor Necrosis Factor (TNF) activity is a successful therapeutic approach for 50–60% of rheumatoid arthritis (RA) patients. However, there are yet no biomarkers to stratify patients for anti-TNF therapy. Rheumatoid factor (RF) and anti-cyclic-citrullinated antibod...

Full description

Bibliographic Details
Main Authors: Antonio Julià, María López-Lasanta, Francisco Blanco, Antonio Gómez, Isabel Haro, Antonio Juan Mas, Alba Erra, Ma Luz García Vivar, Jordi Monfort, Simón Sánchez-Fernández, Isidoro González, Mercedes Alperi, Raúl Castellanos-Moreira, Antonio Fernández-Nebro, César Díaz-Torné, Núria Palau, Raquel Lastra, Jordi Lladós, Raimon Sanmartí, Sara Marsal
Format: Article
Language:English
Published: BMC 2021-04-01
Series:BMC Musculoskeletal Disorders
Subjects:
Rheumatoid arthritis
Treatment response
Anti-TNF therapy
Autoantibodies
Online Access:https://doi.org/10.1186/s12891-021-04248-y

Internet

https://doi.org/10.1186/s12891-021-04248-y

Similar Items